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Abstract A catalytically inactive mutant of hen egg white
lysozyme was constructed by site-directed mutagenesis to
elucidate the role of enzymatic activity on its antimicrobial
activity against Gram-positive bacteria. The catalytic residue
aspartic acid at position 52 of lysozyme was substituted with
serine (D52S-Lz) and the mutant cDNA was inserted into a yeast
expression vector, pYES-2. Western blot analysis indicated that
the mutation did not affect secretion of the D52S-Lz lysozyme
into the medium of the expressing Saccharomyces cerevisiae,
INVSC1. In addition, circular dichroism and fluorescence
spectral analysis revealed no change in the structure of D52S-
Lz compared to that of wild-type (Wt-Lz) lysozyme. The
mutation (D52S) abolished the catalytic activity of lysozyme.
Antimicrobial tests against Staphylococcus aureus and Bacillus
subtilis revealed that the catalytically inactive D52S-Lz was as
bactericidal as the Wt-Lz lysozyme. Heat treatment leading to
enzyme inactivation had no effect on the bactericidal activity of
either wild-type or the mutant D52S-Lz lysozyme. The binding
affinity of D52S-Lz to the isolated peptidoglycan of S. aureus
was unaffected. Our results provide the first demonstration of
direct genetic evidence that the antimicrobial activity of
lysozyme is operationally independent of its muramidase activity,
and strongly suggest the antimicrobial action of lysozyme is due
to structural factors. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Lysozyme is known as a powerful antibacterial protein
widely distributed in various biological £uids and tissues in-
cluding avian egg, plant, bacteria, and animal secretions,
tears, saliva, milk, respiratory and cervical secretions, and
secreted by polymorphonuclear leukocytes [1]. It belongs to
a class of enzymes that lyses the cell walls of certain Gram-
positive bacteria, as it splits the bond between N-acetylglucos-
amine and N-acetylmuramic acid of the peptidoglycan (PG) in
the bacterial cell walls. Beside antimicrobial activity, lysozyme
has many other functions, including inactivation of certain
viruses [2], important roles in surveillance of membranes of
mammalian cells [3], it enhances phagocytic activity of poly-
morphonuclear leukocytes and macrophages [4,5] and stimu-
lates proliferation and antitumor functions of monocytes [6].
Although conclusive evidence is lacking, it has long been
believed that the antimicrobial action of lysozyme would
merely be attributed to its catalytic function on bacterial cell
walls. The importance of lysozyme as an active defense mol-
ecule has been debated, since in most bacteria the PG layer is
not directly accessible to this enzyme. Under physiological
conditions only a minority of Gram-positive bacteria are sus-
ceptible to lysozyme, and it has been suggested that the main
role of lysozyme is to participate in the removal of bacterial
cell walls after the bacteria have been killed by antimicrobial
polypeptides present in egg albumin, insect hemolymph [7] or
by complement in animal serum [8]. This is in line with the
notion that the lytic action of lysozyme does not kill suscep-
tible bacteria under physiological conditions, osmotically bal-
anced [9]. The literature abounds with evidence pertaining to
the functional role of lysozyme in various tissues as a defense
mechanism, suggesting that it may primarily be related to
structural properties and secondarily to its direct bacteriolytic
action [10,11]. Recently, we found that heat denaturation of
lysozyme progressively inactivates the enzyme while greatly
promoting its antimicrobial action to Gram-negative bacteria.
Surprisingly, denatured lysozyme devoid of enzyme activity
exhibited bactericidal activity against Gram-positive bacteria,
suggesting an action independent of catalytic function [12^16].
However, it was hard to obtain concrete evidence that mu-
ramidase activity makes no contribution in lysozyme’s antimi-
crobial activity against Gram-positive bacteria because of the
complex structural changes accompanying thermal inactiva-
tion. It was impossible to discern if the observed antimicrobial
activity is unique to the denatured lysozyme or it is a general
action regardless of structural changes of lysozyme.
In this study, we decided to discriminate between the native
and non-native antimicrobial action of lysozyme and to verify
more precisely the role of muramidase activity in the inherent
antibacterial action of lysozyme. For this, site-directed muta-
genesis was employed to inactivate the enzyme by substituting
one of its two catalytic residues, Asp, with Ser at position 52.
Aspartic acid 52 was selected for this investigation because
mutation of this residue has been reported to abolish mu-
ramidase activity without a¡ecting binding a⁄nity of mutant
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lysozyme to substrate or inhibitor [17^19]. Thus, Asp-52-Ser
mutation would be expected to produce inactive lysozyme
while restoring its native structure as well as substrate binding
ability. We explore here, for the ¢rst time, that the genetically
inactive lysozyme is a potent bactericide against typical Gram-
positive bacteria regardless of its enzyme activity.
2. Materials and methods
2.1. Materials
Micrococcus lysodeikticus, the microbial substrate of lysozyme, was
purchased from Sigma (St. Louis, MO, USA). Oligodeoxyribonucleo-
tides of the mismatching primer (5P-GAGTACCAGCTACGGAAT-
3P) for mutagenesis was synthesized by Takara Shuzo (Kyoto, Japan).
PG from Staphylococcus aureus IFO 14462 was isolated according to
the hot SDS method [20]. Mouse anti-lysozyme monoclonal IgG was
provided by Dr. Y. Yamaguchi (Fukuyama University, Japan). All
other chemicals were of the highest grade commercially available.
2.2. Bacterial strains and plasmids
Bacterial strains used were Escherichia coli TOP10FP
(FP(laclqTn10(TetR))mcrA v(mrr-hsdRMS-mcrBC) P80lacZvM15
vlacX74 deoR recA1 araD139 v(ara-leu)7697 galU galK rpsL
endA1 nupG), used as a host cell in DNA manipulation, and Saccha-
romyces cerevisiae INVSC1 (MATK, his3-D1, leu2, trp1-289, ura3-52),
an expression yeast. The pYES-2 plasmid, a yeast expression vector,
was purchased from Invitrogen (San Diego, CA, USA). Staphylococ-
cus aureus IFO 14462, Bacillus subtilis IFO 3007 and Bacillus cereus
IFO 13690 were obtained from the Institute of Fermentation (Osaka,
Japan) as test microorganisms for antimicrobial assays. M13 mp19
bacteriophage was from Takara Shuzo. The pKK1 plasmid, which
contains the full length of the pre-lysozyme cDNA, was provided by
Dr. I. Kumagai, University of Tokyo, Japan.
2.3. Site-directed mutagenesis and construction of expression plasmid
The small EcoRI-HindIII fragment of pKK1 [21], containing the
full length of pre-lysozyme cDNA (Wt-Lz), was inserted into M13
mp19 and the single stranded plasmid was used for site-directed muta-
genesis. The mutant lysozyme cDNA (D52S-Lz), having the catalytic
aspartic acid 52 residue substituted with serine, was constructed by
using the mutagenic oligonucleotide primer, 5P-GAGTACCAGC-
TACGGAAT-3P, with the Sculptor in vitro mutagenesis system
(RPN 1526) (Amersham, UK). The mutation was con¢rmed by
DNA sequencing. The small EcoRI-SphI fragment of the full length
of mutant or wild-type cDNAs was ligated with the large EcoRI-SphI
fragment of the pYES-2 expression vector downstream of the GAL1
promoter and upstream of the CYC1 transcription terminator. The
expression plasmids of the wild-type and mutant lysozyme were
termed pYES-Wt and pYES-D52S, respectively.
2.4. Expression of mutant lysozyme in yeast
The yeast expression vectors pYES-Wt and pYES-D52S were trans-
formed to S. cerevisiae INVSC1 according to the lithium acetate
method [22]. The transformants were selected on ura3 yeast minimal
medium (YMM) agar plates. The transformant yeasts were inoculated
into 10 ml of YMM-ura3 (containing 0.1% glucose and 5% glycerol)
and incubated for 24 h at 29‡C with shaking. This pre-culture was
then transferred to 1 l of the same medium in a 3 l £ask at 29‡C with
shaking. When the absorbance (A600) of the culture reached 0.3^0.5,
expression was induced by adding the appropriate amount of a con-
centrated stock solution of (¢lter-sterilized) galactose to a ¢nal con-
centration of 2%. Shaking was continued for 8^10 h at 29‡C.
2.5. Puri¢cation of mutant D52S lysozyme
The induced culture of S. cerevisiae INVSC1 was centrifuged at
5000Ug for 10 min at 4‡C. The supernatant was diluted four times
with deionized water and applied to a CM-Toyopearl 650 column
(1.5U5.0 cm) equilibrated with 50 mM Tris^HCl bu¡er (pH 7.5),
and after washing protein was eluted with the same bu¡er containing
0.5 M NaCl. Fractions containing lysozyme were pooled, diluted
10 times with the same bu¡er and rechromatographed on a CM-
Toyopearl 650 column (1.5U10 cm). The lysozyme was eluted with
a linear gradient of 0^0.5 M NaCl in the same bu¡er. The fractions
(3 ml) containing lysozyme were collected and dialyzed in a Spectra/
por dialysis tube (Mr 6000^8000 Da cut-o¡) against distilled water.
The peaks were vacuum-concentrated in a SpeedVac centrifuge. Pro-
tein concentration of the secreted lysozymes was estimated from the
digital image of the SDS^PAGE gel, under reducing conditions, by
Electrophoretic Documentation Analysis System 120 (EDAS 120)
equipped with a DC120 Camera and Kodak ID 2.02 image analysis
software (Eastman Kodak Co., New York, NY, USA), using the
band intensity of authentic hen egg white lysozyme as a standard.
2.6. Muramidase activity assay
The lysis of M. lysodeikticus cells was determined according to the
turbidimetric method, previously reported [13], based on the decrease
in turbidity of a 1.9 ml cell suspension (170 Wg dry cells/ml) in 50 mM
potassium phosphate bu¡er (pH 6.2) following the addition of a
100 Wl portion of the pooled fractions or the puri¢ed lysozyme solu-
tion (20^160 Wg/ml distilled water) after equilibration to achieve con-
stant absorbance (0.75^0.8). For the pH activity pro¢le 50 mM bu¡er
of Na-acetate (pH 4.0^6.0) or K-phosphate (pH 6.0^8.5) was used.
The decrease in absorbance at 450 nm (25‡C) was monitored using a
Hitachi U-2000 recording spectrophotometer. The activity is ex-
pressed as the rate of decrease in absorbance per minute.
2.7. Sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS^PAGE)
SDS^PAGE, under reducing conditions (5% L-mercaptoethanol),
was performed using a 5% acrylamide stacking gel and 15% separat-
ing gel containing 0.1% SDS according to the method of Laemmli
[23]. Protein bands were visualized by Coomassie brilliant blue R-250
(CBB).
2.8. Immunoblotting
Immunoblot analysis of the recombinant lysozyme (Wt-Lz and
D52S-Lz) was performed after resolving the protein bands on SDS^
PAGE (5^15% acrylamide gel) as described above. The protein bands
in the gel were electroblotted onto a polyvinylidene di£uoride (PVDF)
membrane by a semidry unit at 0.8 mA/cm2 for 30 min, using the
Towbin bu¡er system [24]. The blots were blocked by 2% bovine
serum albumin (BSA), and then immunostained using mouse anti-
lysozyme monoclonal IgG and secondary goat anti-mouse IgG alka-
line phosphatase-conjugated antibody.
2.9. Antibacterial assay
The liquid broth method [25] was used to assess the bactericidal
activity of the recombinant proteins. Mid-logarithmic phase cells,
grown in BHI broth, were washed and resuspended (to give 2U106
cells/ml) in a bu¡ered Bacto-peptone broth (pH 7.4). Each bacterial
suspension (100 Wl) was mixed with an equal volume of the same
medium containing the test lysozyme (¢nal concentration 50 Wg/ml).
Controls were incubated in the absence of protein. The mixture was
incubated at 30‡C for 1 h, then a 30 Wl portion or dilutions (in 0.85%
saline) were spotted onto nutrient agar plates. The colony-forming
units (CFU) were obtained after incubating the agar plates at 37‡C
for 18 h. All assays were performed in triplicate and the results, unless
otherwise noted, are the means of three independent experiments.
2.10. PG binding assay by enzyme-linked immunosorbent assay
Microtiter plates (96 wells) were coated with puri¢ed PG of
S. aureus by incubating 100 Wl/well (10 Wg/ml in 0.1 M Na2CO3,
pH 9.6) at 37‡C for 3 h. After rinsing and blocking with BSA, lyso-
zyme sample was allowed to interact for 1 h at 37‡C, and then £icked
out. Mouse anti-lysozyme IgG monoclonal IgG was incubated with
the plates for 1 h, and then was substituted with the alkaline phos-
phatase-conjugated goat anti-mouse IgG for 1 h. A 100 Wl aliquot of
0.1% of p-nitrophenylphosphate-Na2 in diethanolamine bu¡er (pH
9.8) was added and incubated at 25‡C until su⁄cient color had de-
veloped. The reaction was stopped by addition of 50 Wl/well of 2 N
NaOH, and absorbance at 405 nm was measured in a microtiter plate
reader. Mean absorbance and S.E.M. were calculated after subtract-
ing the value of controls from four replications of each well.
3. Results
It was deduced from a detailed analysis of the complex
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between lysozyme and hexamer of N-acetylglucosamine by
X-ray crystallography that Glu-35 and Asp-52 are the cata-
lytic residues [26]. The mutation of Glu-35 to Asp or Asp-52
to Glu in hen [27] or human [28] lysozyme caused inactivation
of the enzyme. Glu-35 participates in catalysis in protonated
form and Asp-52 does so in dissociated form. A covalent
complex between mutant Asp-52-Ser lysozyme and substrate
oligosaccharides was detected by electrospray mass spectrom-
etry [19], however, because there is no system to remove the
sugar intermediate the hydrolysis was improbable [18]. Ac-
cordingly, in order to keep the molecular dynamics as well
as the binding ability of the inactive mutant lysozyme to
PG unchanged we chose the substitution of Asp-52 by serine
that will be the most appropriate for the purpose of this in-
vestigation.
3.1. Expression and puri¢cation of D52S-Lz
Upon induction of expression with galactose, a considerable
amount of the mutant D52S-Lz and Wt-Lz lysozyme was
secreted in the culture medium of yeast. Both recombinant
lysozymes were eluted, with a linear gradient of 0^0.5 M
NaCl, from the CM-Toyopearl 650 column at the same posi-
tion (Fig. 1). The peak of D52S-Lz did not show muramidase
activity, assessed by using M. lysodeikticus cell walls as sub-
strate, in any fraction (Fig. 1B). To con¢rm that the secreted
mutant protein, which has no enzyme activity, is lysozyme,
the puri¢ed peaks were run on SDS^PAGE under reducing
Fig. 1. Puri¢cation of Wt-Lz (A) and D52S-Lz (B) lysozymes from yeast medium on a CM-Toyopearl 650 column. The transformant S. cerevi-
siae INVSC1, harboring vectors pYES-Wt or pYES-D52S, grown to late log phase (A600W0.5) in YMM-ura3, then expression was induced for
10 h at 29‡C by the addition of galactose (2%). The cell-free supernatants were applied to a CM-Toyopearl 650 column, then eluted with a lin-
ear gradient of 0^0.5 M NaCl in 50 mM Tris^HCl bu¡er (pH 7.5). The absorbance was monitored at 280 nm (circles), and a portion from
each fraction was checked for muramidase activity against M. lysodeikticus (open squares). C: Protein peaks were dialyzed, vacuum-concen-
trated and applied to reducing SDS^PAGE and protein bands were visualized with CBB (top) or electroblotted to a PVDF membrane and im-
munostained using mouse anti-NLz monoclonal IgG and alkaline phosphatase-conjugated anti-mouse IgG goat antibody (bottom).
Fig. 2. Muramidase activity of the puri¢ed Wt-Lz and D52S-Lz ly-
sozymes from INVSC1 yeast medium on a CM-Toyopearl 650 col-
umn. The decrease of turbidity at 450 nm of M. lysodeikticus cell
suspension was monitored in 50 mM K-phosphate bu¡er (pH 6.2),
containing various concentrations of enzyme. Activity is expressed
as the rate of change in absorbance per minute.
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conditions and analyzed on immunoblots stained with speci¢c
monoclonal antibody to hen egg white lysozyme (Fig. 1C).
Protein staining of the gel (Fig. 1C, top) indicated that the
mutant D52S-Lz has electrophoretic mobility similar to that
of Wt-Lz and authentic hen egg white lysozyme (NLz). Im-
munostaining of the blot (Fig. 1C, bottom) identi¢ed the mu-
tant D52S-Lz as lysozyme.
3.2. Enzymatic activity of D52S-Lz
Fig. 2 shows the muramidase activities of authentic Lz, Wt-
Lz and D52S-Lz lysozymes for M. lysodeikticus cells as a
function of lysozyme concentration at pH 6.2. Within the
linear range of lysozyme concentrations (¢nal concentration
0.2^1.8 Wg/ml), the lytic activity of Wt-Lz is almost the same
as that of NLz. However, D52S-Lz showed no enzymatic
activity at any protein concentration tested. The mutant
D52S-Lz was inactive even after extending the reaction time
up to 30 min (data not shown). It should be noted that similar
results of activity were obtained when the enzymatic reaction
was carried out at 37‡C (data not shown). The results con¢rm
that the mutation of Asp-52-Ser abolishes the enzymatic ac-
tivity of lysozyme at neutral pH. Prior to investigating the
antibacterial activity of the muramidase-inactive mutant lyso-
zyme we examined the conformational changes that might
occur with this mutation (Asp-52-Ser). We found that this
mutation did not alter either the secondary or the tertiary
structure of lysozyme as judged by circular dichroism (CD)
and intrinsic £uorescence emission spectra (data not shown).
This demonstrated that the muramidase-inactive lysozyme
(D52S-Lz) restores the same conformation as that of the
Wt-Lz and agrees with the reported crystal structure of the
mutant D52S hen egg white lysozyme [17].
3.3. Antibacterial activity to Gram-positive bacteria
Fig. 3 shows the bactericidal action of Wt-Lz and D52S-Lz
against S. aureus cells. Both Wt-Lz and the mutant D52S-Lz
lysozymes were bactericidal to this strain with approximately
4 and 3.6 log reduction in cell viability, respectively (Fig. 3A).
It was con¢rmed from the pH dependence of the hydrolytic
activity pro¢le, within the range of pH 4^10, that the mutant
Asp-52-Ser is catalytically inactive, while Wt-Lz showed the
common bell-shaped pH^activity pro¢le (Fig. 3A, inset).
Fig. 3. Anti-staphylococcal activity of Wt-Lz and D52S-Lz lyso-
zymes. A: The bactericidal assay was performed by incubating
S. aureus with 50 Wg/ml protein at 30‡C for 1 h, then dilutions were
spotted onto nutrient agar plates. The CFU were obtained after in-
cubating the plates at 37‡C for 18 h. Inset: pH^activity pro¢le of
Wt-Lz and D52S-Lz (¢nal concentration 3.4 Wg lysozyme/ml) as de-
scribed in Section 2. B: Wt-Lz and D52S-Lz were heat-denatured in
10 mM Na-phosphate bu¡er (pH 6.0) and tested for anti-staphylo-
coccal activity. Inset: Muramidase activity of Wt-Lz and D52S-Lz
upon heat denaturation at di¡erent protein concentrations.
Fig. 4. Antibacterial activity against B. subtilis of Wt-Lz and D52S-
Lz lysozymes. A: The bactericidal assay was performed as described
for S. aureus in the legend of Fig. 3A. B: Antibacterial activity
against B. subtilis of heat-denatured Wt-Lz and D52S-Lz as de-
scribed for S. aureus in the legend of Fig. 3B.
FEBS 25270 26-9-01
H.R. Ibrahim et al./FEBS Letters 506 (2001) 27^3230
Wild-type lysozyme exhibited the maximum lytic activity at
pH 7.4, the pH at which the antibacterial assay was per-
formed. From the results of Fig. 3A, it is apparent therefore
that hydrolysis of PG in the cell walls and the killing of
bacteria by lysozyme are two independent processes. This
was further con¢rmed by testing the antibacterial activity
upon heat-induced inactivation of both constructs (Fig. 3B).
The heat-inactivated Wt-Lz and D52S-Lz exhibited the same
antibacterial potency against S. aureus regardless of residual
enzyme activity (Fig. 3B, inset). Furthermore, both constructs
Wt-Lz and D52S-Lz showed a remarkable in vitro bactericidal
activity against two other Gram-positive strains, B. subtilis
(Fig. 4) and B. cereus (data not shown; identical to the data
in Fig. 4). Interestingly, the enzymatically inactive D52S-Lz
exhibited stronger activity, more than one log of killing,
against B. subtilis than Wt-Lz (Fig. 4A). However, upon
heat-induced inactivation both D52S-Lz and Wt-Lz exerted
a comparably strong bactericidal activity against B. subtilis
(Fig. 4B) and also B. cereus (data not shown).
3.4. Binding capacity to isolated PG of S. aureus
Lysozyme interacts with Gram-positive bacteria by initially
binding to PG of the cell walls. We investigated the interac-
tion between the mutant D52S-Lz and isolated PG from
S. aureus. Both D52S-Lz and Wt-Lz were found to exhibit
essentially similar binding a⁄nity to PG (Fig. 5). At low con-
centrations the binding of Wt-Lz to PG was slightly more
pronounced than D52S-Lz. This might be ascribed to the
previous observation that the (N-acetylglucosamine)4^D52S
complex portrays a distorted, sofa conformation for subsite
D [17]. However, the results indicate that mutation did not
unfavorably alter the binding to the bacterial cell walls.
4. Discussion
Although structural and physiological [29,30] as well as
enzymatic [1,28] characteristics of lysozyme have been clearly
elucidated, its structure^bactericidal relationship has yet to be
fully understood. Recently, we suggested that the antimicro-
bial action of lysozyme is related to conformational changes
and seems to be decoupled from its enzyme activity. The study
involved irreversible heat denaturation at di¡erent pHs
[12,13,15,16]. However, because heat-denatured lysozyme has
a non-native conformation, it is still not certain that the en-
zymatic activity of lysozyme makes a contribution to the anti-
bacterial action, particularly against the lysozyme-sensitive
Gram-positive bacteria.
The results of this study provide the ¢rst demonstration of
direct genetic evidence that the principal bactericidal action of
lysozyme against the Gram-positive bacteria S. aureus and
B. subtilis was independent of its catalytic function (Figs. 3
and 4). It is of general interest that the mutant D52S-Lz has a
fairly stronger bactericidal activity against B. subtilis than
Wt-Lz (Fig. 4A). Since both Wt-Lz and D52S-Lz have the
same antibacterial potency when heat-denatured (Figs. 3B
and 4B), the results support the conclusion that the killing
of these typical Gram-positive bacteria would be ascribed to
structural features of the lysozyme molecule rather than enzy-
matic bacteriolysis. However, monitoring the absorbance (at
600 nm) of B. subtilis cell suspensions in the presence of the
muramidase-inactive mutant (D52S-Lz) revealed considerable
bacterial lysis (data not shown). This striking datum thus in-
dicates that the killing of Gram-positive bacteria by lysozyme
is basically a bacteriolytic action but operationally independ-
ent of its muramidase activity. Given the fact that both Wt-Lz
and D52S-Lz have almost the same e⁄ciency in binding bac-
terial PG (Fig. 5), the killing of these typical Gram-positive
bacteria involves interaction with the bacterial cell walls. Most
likely the initial attraction between the positively charged ly-
sozyme and the negatively charged bacterial surface (PG)
seems to be based on electrostatic forces.
It is of interest to note that the potency of Wt-Lz and
D52S-Lz against B. subtilis di¡ered (Fig. 4A). Because the
structure of D52S-Lz was indistinguishable from that of Wt-
Lz, as revealed by CD and intrinsic £uorescence emission
spectra, it is likely that the di¡erence in their antibacterial
response against B. subtilis would be ascribed to the interfer-
ence of muramidase activity of Wt-Lz to the structure-related
action (Fig. 4A). These results seem contradictory, but appar-
ently the main mode of bactericidal action against Gram-pos-
itive bacteria involves the existence of some microbe-associ-
ated target of lysozyme, other than direct hydrolysis of PG.
This observation is in agreement with the note that bacterial
autolysins play an essential role in expression of the bacter-
icidal activity of lysozyme against oral micro£ora [11]. It has
also been reported that cell death of B. subtilis caused by
surfactants at low concentrations results from induced cell
autolysis [31,32]. These observations together with the results
of the present work suggest that autolysins are involved in
killing and lysis of bacteria by lysozyme that may actually
be induced by intrinsic structural motifs other than murami-
Fig. 5. Solid-phase binding of Wt-Lz and D52S-Lz to the isolated
PG of S. aureus. Wells were coated with PG then blocked with
BSA. Various concentrations of Wt-Lz (solid circles) or D52S-Lz
(open circles) were added. The amount of bound lysozyme was
quantitated by incubation with mouse anti-lysozyme IgG monoclo-
nal IgG then the alkaline phosphatase-conjugated goat anti-mouse
IgG and developed with o-nitrophenyl-L-D-galactoside. Each data
point is the mean of triplicates.
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dase activity. The exploration of the ability of D52S-Lz to
trigger such non-enzymatic mechanisms of microbicidal action
would merit further investigation.
Lysozyme has been recognized as an important factor in the
body’s defense against bacterial [4,33^36] and HIV-1 [37] in-
fections as well as the lysis of tumor cells [6,38^40]. The tan-
talizing question, therefore, is, what is the role muramidase
activity plays in lysozyme’s defense functions? Simply, lyso-
zyme appears to behave like a biological response modi¢er
that elicits host responses by interacting with pathogens or
intestinal bacteria, thus liberating PGs of high and low mo-
lecular weight that become the agents responsible for the spe-
ci¢c immune cell activation. The reported immunostimulatory
activity of lysozyme [3,6] is in support of this conclusion. The
elucidation of the catalytically independent mechanisms of
bactericidal action of D52S-Lz as well as other biological
functions reported for lysozyme is now in progress.
In summary, the data provide the ¢rst direct genetic evi-
dence that the bactericidal action of lysozyme is operationally
independent of its catalytic function. The results suggest two
main modes of catalytically independent bactericidal action of
lysozyme: an indirect bacteriolytic-dependent mode (such as
that against B. subtilis and B. cereus) and a lysis-independent
death mode (such as that against S. aureus). We suggest that
the lysis-dependent mode involves regulation of cell wall-as-
sociated autolysins through a potential molecule that could
bind lysozyme and thus regulate autolytic activities. However,
cell death without lysis is likely to result from impaired mem-
brane functions through the binding of a certain domain of
lysozyme with the bacterial surface. Eventually, the genetic
evidence presented in this study will provide a clearer under-
standing of the mechanism by which lysozyme kills bacteria
and the rules that govern its potency may provide guidance in
drug design.
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